These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 19884574)

  • 1. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort.
    Uc EY; McDermott MP; Marder KS; Anderson SW; Litvan I; Como PG; Auinger P; Chou KL; Growdon JC;
    Neurology; 2009 Nov; 73(18):1469-77. PubMed ID: 19884574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study.
    Aarsland D; Brønnick K; Larsen JP; Tysnes OB; Alves G;
    Neurology; 2009 Mar; 72(13):1121-6. PubMed ID: 19020293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with cognitive impairment in patients with Parkinson disease: an urban study.
    Rosdinom R; Fazli A; Ruzyanei NJ; Azlin B; Srijit D
    Clin Ter; 2011; 162(1):23-9. PubMed ID: 21448542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.
    Vu TC; Nutt JG; Holford NH
    Br J Clin Pharmacol; 2012 Aug; 74(2):284-95. PubMed ID: 22300470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
    Shoulson I
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive impairment in early-stage non-demented Parkinson's disease patients.
    Pfeiffer HC; Løkkegaard A; Zoetmulder M; Friberg L; Werdelin L
    Acta Neurol Scand; 2014 May; 129(5):307-18. PubMed ID: 24117192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.
    Liu C; Cholerton B; Shi M; Ginghina C; Cain KC; Auinger P; ; Zhang J
    Parkinsonism Relat Disord; 2015 Mar; 21(3):271-6. PubMed ID: 25596881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.
    Stewart T; Liu C; Ginghina C; Cain KC; Auinger P; Cholerton B; Shi M; Zhang J;
    Am J Pathol; 2014 Apr; 184(4):966-975. PubMed ID: 24625392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group.
    Kieburtz K; McDermott M; Como P; Growdon J; Brady J; Carter J; Huber S; Kanigan B; Landow E; Rudolph A
    Neurology; 1994 Sep; 44(9):1756-9. PubMed ID: 7936311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
    Schneider JS; Elm JJ; Parashos SA; Ravina BM; Galpern WR;
    Parkinsonism Relat Disord; 2010 Sep; 16(8):507-12. PubMed ID: 20598621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score.
    Nazem S; Siderowf AD; Duda JE; Have TT; Colcher A; Horn SS; Moberg PJ; Wilkinson JR; Hurtig HI; Stern MB; Weintraub D
    J Am Geriatr Soc; 2009 Feb; 57(2):304-8. PubMed ID: 19170786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD).
    Riedel O; Klotsche J; Spottke A; Deuschl G; Förstl H; Henn F; Heuser I; Oertel W; Reichmann H; Riederer P; Trenkwalder C; Dodel R; Wittchen HU
    J Neurol; 2008 Feb; 255(2):255-64. PubMed ID: 18204803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores.
    Mamikonyan E; Moberg PJ; Siderowf A; Duda JE; Have TT; Hurtig HI; Stern MB; Weintraub D
    Parkinsonism Relat Disord; 2009 Mar; 15(3):226-31. PubMed ID: 18595765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.
    Marras C; McDermott MP; Rochon PA; Tanner CM; Naglie G; Lang AE;
    Mov Disord; 2008 Apr; 23(5):653-9; quiz 776. PubMed ID: 18076084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Premotor cognitive status in a cohort of incident Parkinson disease patients (NEDICES).
    Sánchez-Ferro Á; Benito-León J; Mitchell AJ; Louis ED; Posada IJ; Trincado R; Villarejo A; Bermejo-Pareja F
    J Neurol Sci; 2011 Nov; 310(1-2):211-5. PubMed ID: 21621225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease.
    Christine CW; Auinger P; Joslin A; Yelpaala Y; Green R;
    Mov Disord; 2018 May; 33(5):762-770. PubMed ID: 29508904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on the status of cognition among Parkinson's disease patients in Xi'an.].
    Wang RL; Qu QM; Cao HM; Zhe X; Qiao J; Guo F
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Mar; 31(3):329-32. PubMed ID: 20510065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Greater intraindividual variability in neuropsychological performance predicts cognitive impairment in de novo Parkinson's disease.
    Jones JD; Burroughs M; Apodaca M; Bunch J
    Neuropsychology; 2020 Jan; 34(1):24-30. PubMed ID: 31219297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autonomic and cognitive functions in Parkinson's disease (PD).
    Oh ES; Lee JH; Seo JG; Sohn EH; Lee AY
    Arch Gerontol Geriatr; 2011; 52(1):84-8. PubMed ID: 20223528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.